Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

Gianluca Masi, Fotios Loupakis, Luca Pollina, Enrico Vasile, Samanta Cupini, Sergio Ricci, Isa Maura Brunetti, Roberta Ferraldeschi, Giuseppe Naso, Franco Filipponi, Andrea Pietrabissa, Orlando Goletti, Giacomo Baldi, Lorenzo Fornaro, Michele Andreuccetti, Alfredo Falcone

Research output: Contribution to journalArticle

Abstract

OBJECTIVE/BACKGROUND: The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection of metastases in initially unresectable metastatic colorectal cancer. The objective of this study was to evaluate the long-term outcome of resected patients and the impact of FOLFOXIRI on perioperative morbidities, mortality, and chemotherapy induced hepatotoxicity. PATIENTS AND METHODS: Overall, 196 patients with initially unresectable metastatic colorectal cancer were treated with FOLFOXIRI in 2 phase II and 1 phase III trial. This regimen was associated with an elevated response rate (70.4%) and 37 patients (19%) could undergo a secondary R0 surgery on metastases. This study was registered with the Australian New Zealand Clinical Trials Registry Database at http://www.anzctr.org.au/Statistics.aspx and has ID number ACTRN12608000615381. RESULTS: Main characteristics of the 37 radically resected patients were: median age 64 years (45-73), Eastern Cooperative Oncology Group Performance Status (ECOG) PS ≥1 in 30%, synchronous metastases in 65%, multiple sites of disease in 22%, and metastases confined to the liver in 68%. Preoperative FOLFOXIRI was administered for a median of 5.5 months. There was no perioperative mortality and all morbidities (27% of patients) resolved without sequelae. After a median follow up of 67 months, 5-year and 8-year survival are 42% and 33% respectively. At 5 years, 29% of patients are free of disease. The analysis of treatment-induced liver injury showed neither G3 vascular toxicity nor G4 steatosis, and steato-hepatitis in only 5% of patients. CONCLUSIONS: The GONO-FOLFOXIRI regimen allow an R0 surgery in approximately 1 out of 5 unselected patients with initially unresectable metastatic colorectal cancer, and the long-term survival of resected patients is considerable. Neoadjuvant FOLFOXIRI for 3-6 months is safe and not associated with severe liver injury.

Original languageEnglish
Pages (from-to)420-425
Number of pages6
JournalAnnals of Surgery
Volume249
Issue number3
DOIs
Publication statusPublished - Mar 2009

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases'. Together they form a unique fingerprint.

  • Cite this

    Masi, G., Loupakis, F., Pollina, L., Vasile, E., Cupini, S., Ricci, S., Brunetti, I. M., Ferraldeschi, R., Naso, G., Filipponi, F., Pietrabissa, A., Goletti, O., Baldi, G., Fornaro, L., Andreuccetti, M., & Falcone, A. (2009). Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Annals of Surgery, 249(3), 420-425. https://doi.org/10.1097/SLA.0b013e31819a0486